<DOC>
	<DOCNO>NCT02827851</DOCNO>
	<brief_summary>Stromal vascular fraction cell ( SVF ) extract lipoaspirate enzymatic digestion . SVF administer single dose intraarticularly 4 week arthroscopic debridement . All patient receive cell therapy.This single arm study control .</brief_summary>
	<brief_title>Autologous Stromal Vascular Fraction Cells Treatment Knee Articular Cartilage Dystrophy</brief_title>
	<detailed_description>Patients undergone arthroscopic debridement knee osteoarthritis subject abdominal liposuction local anaesthesia . Harvested adipose tissue process accord patent pending technology base enzymatic digestion , wash concentration cell pellet 5 ml Hartmann 's solution . Isolated SVF administer single dose anterior part knee joint cavity 28 day arthroscopy .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Pain knee joint half day assess Visual Analog Pain Scale ( score 40 mm ) At least three follow 6 criterion : 50 year age old , stiffness last less 30 minute , crepitus , bony tenderness , bony enlargement , warmth touch Patient able walk without assistance Patient familiar Participant information sheet Patient sign informed consent form Noninclusion Criteria : Medical history endoprosthetic knee replacement Medical history low extremity osteotomy Medical history knee surgery ( include arthroscopy ) precede 1 year prior enrollment Medical history intraarticular injection precede 6 month prior enrollment Secondary osteoarthritis knee joint : posttraumatic osteoarthritis ( develop clinically significant injury ) , intraarticular fracture , clinically significant varus valgus deformity low limb , septic arthritis , joint 's inflammatory disorder , gout , advanced chondrocalcinosis , Paget 's disease , ochronosis , acromegaly , hemochromatosis , Wilson 's disease , primary synovial osteochondromatosis , osteonecrosis , hemophilia Patients prescribed immunosuppressive treatment Medical history systemic autoimmune inflammatory diseases Significant weight loss ( &gt; 10 % body weight previous year ) unknown etiology Medical history venous thromboembolism estimate high risk venous thromboembolism Patients prescribed systemic corticosteroid medication treatment proven impact bone cartilage tissue metabolism Clinically significant abnormality result laboratory test Any condition limit compliance ( dementia , neuropsychiatric disease , drug alcohol abuse etc . ) Participation clinical trial ( administration investigational drug ) 3 month prior inclusion Patients malignant tumor include postoperative period , patient receive chemotherapy and/or radiotherapy . Patient 's activate partial thromboplastin time exceed normal level 1,8 time Patients prescribed anticoagulant treatment patient receive anticoagulant least one hour prior liposuction Medical history heterotopic ossification Patients prescribed glycoprotein inhibitor treatment Patient 's refusal participation trial Patient 's refusal compliance requirement contraception participation research Chronic kidney disease IV V stage ( creatinine clearance &lt; 30 mL/min estimate CockcroftGault formula ) Confirmed syphilis , HIV , hepatitis B C infection Dropout Criteria : Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Damage articular cartilage</keyword>
	<keyword>Cartilage degeneration</keyword>
	<keyword>Intraarticular injection</keyword>
	<keyword>SVF</keyword>
	<keyword>Stromal vascular fraction</keyword>
	<keyword>Adipose-derived regenerative cell ( ADRC )</keyword>
	<keyword>Adipose tissue</keyword>
	<keyword>Stem cell</keyword>
</DOC>